title: Reply to M.G. McNamara et al and M.S. Copur et al.
authors.affiliation: Basser Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA Susan.domchek@uphs.upenn.edu.
authors.forename: Susan M
authors.initials: SM
authors.lastname: Domchek
authors.affiliation: Sheba Medical Center, Tel Hashomer, Israel.
authors.forename: Bella
authors.initials: B
authors.lastname: Kaufman
authors.affiliation: Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
authors.forename: Michael
authors.initials: M
authors.lastname: Friedlander
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D005260:Female; D018095:Germ-Line Mutation; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D010793:Phthalazines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; D024682:BRCA2 Protein; D010793:Phthalazines; D010879:Piperazines